PIII — P3 Health Partners Inc.

P3 Health Partners Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Membership: Approximately 116,000 members, consistent with expectations.
• Capitated Revenue: $341.6 million, translating to about $982 per member per month (PMPM).
• Adjusted EBITDA: Loss of $45.9 million for the quarter; year-to-date adjusted EBITDA loss of $85.2 million. Normalized adjusted EBITDA loss year-to-date was approximately $70 million.
• Medical Margin: $4.4 million for the quarter ($13 PMPM), compared to $500,000 ($1 PMPM) in the prior year.
• Operating Expenses: Reduced to $21.1 million from $31.6 million year-over-year, a 33% improvement.

2. Strategic Updates and Business Highlights

• Operational Improvements: The company has embedded an operational improvement plan leading to over $100 million in EBITDA improvement year-over-year.
• Joint Venture: A strategic joint venture is expected to add approximately 13,000 fully accretive ACO members, enhancing profitability and cash flow.
• Provider Network Rationalization: The company is exiting non-aligned provider groups to improve margin performance and focusing on Tier 1 providers who deliver better outcomes.
• Care Enablement Model: Continued execution of this model is showing positive results in clinical support and cost management.

3. Forward Guidance and Outlook

• Revised Full-Year EBITDA Guidance: Adjusted to a loss range of $110 million to $95 million, reflecting improved operational visibility and predictability.
• 2026 Outlook: P3 Health anticipates meaningful profitability in 2026, supported by identified EBITDA expansion opportunities of $120 million to $170 million, driven by improved alignment with population health needs and scaling clinical programs.

4. Bad News, Challenges, or Points of Concern

• Adjusted Guidance: The reduction in guidance was attributed to unfavorable midyear settlements and delays in medical cost initiatives, indicating ongoing operational challenges.
• Prior Period Adjustments: A $24 million unfavorable impact in Q3 due to midyear true-ups highlights issues with visibility and data accuracy from payors.
• Market Headwinds: Continued headwinds from specific markets and non-core assets are affecting performance, with expectations for improvement tied to contractual adjustments in 2026.

5. Notable Q&A Insights

• Renegotiation Efforts: CEO Aric Coffman emphasized the need for payors to recognize the value of P3's investments in managing high-risk patients, suggesting that improved benefit designs are expected to align with their goals.
• Skin in the Game: Discussions around aligning incentives with payors were highlighted, with a focus on ensuring accountability for outcomes.
• Future Visibility: CFO Leif Pedersen noted that improved controls and processes are being implemented to enhance visibility and reduce the likelihood of future prior period adjustments.
• PMPM Revenue Growth: The company expects a 5% increase in premium rates for 2026, with additional improvements anticipated from enhanced coding practices.

Overall, P3 Health Partners is navigating a transitional year with a focus on operational stability and strategic growth, while addressing challenges related to financial performance and market dynamics.